BioCryst Pharmaceuticals (NASDAQ:BCRX) Reaches New 12-Month Low at $4.44

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) hit a new 52-week low during mid-day trading on Friday . The stock traded as low as $4.44 and last traded at $4.47, with a volume of 668065 shares changing hands. The stock had previously closed at $4.50.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC restated a “buy” rating and issued a $12.00 price objective on shares of BioCryst Pharmaceuticals in a report on Wednesday, April 10th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $13.83.

BioCryst Pharmaceuticals Price Performance

The stock has a market capitalization of $913.24 million, a P/E ratio of -3.75 and a beta of 1.90. The stock’s fifty day moving average is $5.21 and its two-hundred day moving average is $5.60.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, February 26th. The biotechnology company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). The firm had revenue of $93.40 million during the quarter, compared to the consensus estimate of $89.19 million. Analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.68 EPS for the current year.

Institutional Trading of BioCryst Pharmaceuticals

A number of hedge funds have recently bought and sold shares of BCRX. Fifth Third Bancorp increased its position in shares of BioCryst Pharmaceuticals by 17,500.0% in the third quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 3,500 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in BioCryst Pharmaceuticals by 96.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 2,388 shares during the period. Fairfield Bush & CO. purchased a new position in BioCryst Pharmaceuticals during the 1st quarter worth approximately $34,000. State of Wyoming purchased a new position in BioCryst Pharmaceuticals during the 4th quarter worth approximately $35,000. Finally, Advisory Services Network LLC raised its stake in BioCryst Pharmaceuticals by 46.3% during the 1st quarter. Advisory Services Network LLC now owns 4,740 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 1,500 shares during the period. 85.88% of the stock is owned by hedge funds and other institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.